| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Naltrexone / bupropion |
| Brand | Mysimba® |
| Indication | Is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with a BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities. |
| Assessment Process | |
| Rapid review commissioned | 12/03/2017 |
| Rapid review completed | 28/03/2017 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 29/03/2017 |
| Pre-submission consultation with Applicant | 29/05/2017 |
| Full submission received from Applicant | 06/11/2017 |
| Preliminary review sent to Applicant | 05/01/2018 |
| NCPE assessment re-commenced | 01/02/2018 |
| Factual accuracy sent to Applicant | 24/04/2018 |
| NCPE assessment re-commenced | 01/05/2018 |
| NCPE assessment completed | 09/05/2018 |
| NCPE assessment outcome | The NCPE recommends that naltrexone/bupropion (Mysimba ®) should not be considered for reimbursement. |
This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.